Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.56 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30665600 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL31606440 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL29420330 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL16979764 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL16983787 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL30839331 | 0.94 | P2RY2 (0.57) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL23140717 | 0.92 | RNASEL (0.54) | P2RY1RNASELP2RY2 | |
| SCHEMBL23157150 | 0.92 | RNASEL (0.54) | P2RY1RNASELP2RY2 | |
| SCHEMBL23140716 | 0.92 | RNASEL (0.54) | P2RY1RNASELP2RY2 | |
| SCHEMBL30632043 | 0.91 | DTYMK (0.66) | POLBENPP1P2RY1RNASELP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125741-A1 | Methods and Systems for Multiplex Gene Amplification from Ultra-Low DNA Input Amounts and Uses Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4594508-A2 | SLC26A4 REGULATORY ELEMENTS AND USES THEREOF | Decibel Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| US-12247200-B2 | Compositions and methods for generating massively parallel nucleic acid sequencing libraries | BIOO SCIENTIFIC CORPORATION (US) | 2025-03-11 | — | — | US | claimed |
| WO-2024099575-A1 | ARTIFICIAL NUCLEIC ACIDS FOR SITE-DIRECTED EDITING OF A TARGET RNA | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2024-05-16 | — | — | WO | claimed |
| WO-2024073635-A2 | SLC26A4 REGULATORY ELEMENTS AND USES THEREOF | Decibel Therapeutics, Inc. (US) | 2024-04-04 | — | — | WO | claimed |
| US-20220098640-A1 | Methods and Systems for Multiplex Gene Amplification from Ultra-Low DNA Input Amounts and Uses Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-03-31 | — | — | US | claimed |
| WO-2026099341-A1 | BIOCONTAINMENT OF UNWANTED ENGINEERED CELLS USING NON-NATURAL AMINO ACIDS | SNIPR BIOME APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125741-A1 | Methods and Systems for Multiplex Gene Amplification from Ultra-Low DNA Input Amounts and Uses Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260109980-A1 | RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS | UNIV COLUMBIA (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260110001-A1 | RECOMBINANT TYPE I-F3 TRANSPOSON-ASSOCIATED CRISPR-CAS SYSTEMS AND METHODS OF USE | UNIV NORTH CAROLINA STATE (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260104409-A1 | NEXT-GENERATION SEQUENCING FOR PROTEIN MEASUREMENT | SOMALOGIC OPERATING CO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | APTAH BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260057967-A1 | METHOD FOR PREDICTING THE MELTING TEMPERATURE OF OLIGONUCLEOTIDE | SEEGENE INC (KR) | 2026-02-26 | — | — | US | disclosed |
| EP-4168578-A1 | COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION | Nanostring Technologies, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230047776-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATIONS | APTAH BIO, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2023288111-A2 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATION | APTAH BIO, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022243659-A1 | DNAZYME DESIGN | UNIVERSITY OF ESSEX ENTERPRISES LIMITED (GB) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022213153-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2022-10-13 | — | — | WO | disclosed |
| US-20220307050-A1 | NON-VIRAL TRANSGENESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220098640-A1 | Methods and Systems for Multiplex Gene Amplification from Ultra-Low DNA Input Amounts and Uses Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | RPRD2, RTCB, UPF1 | POLB 224/4885ENPP1 899/4885P2RY1 2805/4885 |
| US-20260104409-A1 | NEXT-GENERATION SEQUENCING FOR PROTEIN MEASUREMENT | PABPC4, MAX, FUS | POLB 1781/4885ENPP1 1212/4885P2RY1 461/4885 |
| US-20260109980-A1 | RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS | ZFR, LUC7L2, SLIRP | POLB 428/4885ENPP1 3886/4885P2RY1 4387/4885 |
| US-20260125741-A1 | Methods and Systems for Multiplex Gene Amplification from Ultra-Low DNA Input Amounts and Uses Thereof | DNMT3A, DCTD, POLL | POLB 14/4885ENPP1 1917/4885P2RY1 1336/4885 |
| US-20260057967-A1 | METHOD FOR PREDICTING THE MELTING TEMPERATURE OF OLIGONUCLEOTIDE | TPR, POLM, POLRMT | POLB 53/4885ENPP1 1489/4885P2RY1 2531/4885 |
| US-20260110001-A1 | RECOMBINANT TYPE I-F3 TRANSPOSON-ASSOCIATED CRISPR-CAS SYSTEMS AND METHODS OF USE | RNGTT, LUC7L2, MUS81 | POLB 915/4885ENPP1 4031/4885P2RY1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.